The original success of the copyright undeniably transformed the medication landscape, but investing in companies heavily reliant on generic versions presents a complex picture. Despite early profits were substantial, the expiration of patents and the emergence of cheaper alternatives have diminished sales. Therefore, a thorough analysis of current